Rioci 1
Rioci 1 is riociguat 1 mg tablets — the first soluble guanylate cyclase (sGC) stimulator, originally Bayer Adempas (2013). Approved for pulmonary arterial hypertension (PAH, WHO Group 1) and the only oral drug for inoperable chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4). PATENT-1 and CHEST-1 trial evidence. Specialist-managed disease — not ordinary hypertension. Contraindicated with PDE5 inhibitors and nitrates.
✓ Medically reviewed by Morgan Ellis — Pharmacy Researcher · 8 years experience · Last reviewed: May 2026
⚡ Quick Answer — What is Rioci 1?
Rioci 1 is 1 mg riociguat tablets from a WHO-GMP certified manufacturer — a soluble guanylate cyclase (sGC) stimulator for pulmonary arterial hypertension (PAH). PAH is a specific, progressive, and rare disease — not the same as systemic hypertension. It raises pressure in the pulmonary arteries, not the systemic arteries, and requires dedicated specialist-directed therapy at an accredited PAH centre. Riociguat was introduced by Bayer in 2013 as Adempas — the first sGC stimulator approved for human use. FDA-approved for two specific forms of pulmonary hypertension: pulmonary arterial hypertension (PAH, WHO Group 1) and chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4) — the only oral drug approved for inoperable CTEPH. directly activates soluble guanylate cyclase (the NO receptor) in pulmonary arterial smooth muscle, raising cGMP and producing pulmonary vasodilation. Unlike PDE5 inhibitors, riociguat stimulates sGC even in the absence of NO, giving activity in NO-deficient vascular beds characteristic of PAH and CTEPH. Dosing: Start 1 mg three times daily (8-hour intervals); titrate every 2 weeks by 0.5 mg increments based on systolic BP (must remain >95 mmHg) and symptoms. Target dose 2.5 mg three times daily. PAH treatment is typically combination therapy initiated and monitored at a specialist centre; this is not a DIY disease.
📦 Every order is covered by our Reshipment Assurance Policy — if your parcel does not arrive within 20 business days, we reship it.
Why order from MedsBase
Our generic medications are sourced from WHO-GMP certified manufacturers and shipped worldwide in discreet, plain packaging — no medication name on the parcel exterior. Card payments are routed through a regulated processor (statement descriptors include a regulated card-payment processor — never “MedsBase” or any medication name). Crypto and SEPA bank transfer are also accepted. Every order is backed by our Reshipment Assurance Policy.
What Is Rioci 1?
Rioci 1 is 1 mg riociguat tablets from a WHO-GMP certified manufacturer, supplied in 10-180 tablets. Riociguat was introduced by Bayer in 2013 as Adempas — the first sGC stimulator approved for human use. FDA-approved for two specific forms of pulmonary hypertension: pulmonary arterial hypertension (PAH, WHO Group 1) and chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4) — the only oral drug approved for inoperable CTEPH.
Pulmonary arterial hypertension (PAH) is not systemic hypertension. PAH refers specifically to raised pressure in the pulmonary arterial circulation (≥20 mmHg mean pulmonary arterial pressure with pulmonary vascular resistance ≥2 Wood Units per 2022 ESC/ERS guidelines). It is rare (estimated 15-50 per million adults), progressive, and without treatment carries a poor prognosis (historical 5-year survival ∼30%). Modern PAH-targeted therapy has improved 5-year survival to 60-70% in expert centres.
Candidates for Rioci 1 have been diagnosed at a PAH specialist centre via right heart catheterisation, with WHO/NYHA functional class II-IV symptoms and confirmed PAH (WHO Group 1) or — for riociguat — inoperable or persistent CTEPH (WHO Group 4). This is not a drug for ordinary hypertension or for self-initiated therapy.
How Riociguat Works
Directly activates soluble guanylate cyclase (the NO receptor) in pulmonary arterial smooth muscle, raising cGMP and producing pulmonary vasodilation. Unlike PDE5 inhibitors, riociguat stimulates sGC even in the absence of NO, giving activity in NO-deficient vascular beds characteristic of PAH and CTEPH.
Evidence
PATENT-1 (2013) — riociguat in 443 PAH patients; 6-minute walk distance improved by 30 m vs placebo, with better WHO functional class and delayed clinical worsening. CHEST-1 (2013) — riociguat in 261 inoperable or persistent CTEPH patients; 6-minute walk improved by 46 m vs placebo.
Dosage and Monitoring
Dosing: Start 1 mg three times daily (8-hour intervals); titrate every 2 weeks by 0.5 mg increments based on systolic BP (must remain >95 mmHg) and symptoms. Target dose 2.5 mg three times daily.
Monitoring: at baseline and every 3-6 months thereafter — WHO functional class, 6-minute walk distance, NT-proBNP, repeat echocardiography, and (at longer intervals) right heart catheterisation. All done through a specialist PAH centre.
BP monitoring: systolic BP must remain >95 mmHg; uptitration paused or reversed on symptomatic hypotension.
Side Effects
- Hypotension — dose-limiting; titrate slowly.
- Haemoptysis — increased risk, especially in CTEPH.
- Syncope
- Headache, dizziness
- Peripheral oedema
- Anaemia
Contraindications
- Concurrent PDE5 inhibitors (sildenafil, tadalafil) — additive cGMP rise, severe hypotension. Contraindicated combination.
- Concurrent nitrates or NO donors — same reason; contraindicated.
- Pregnancy — embryofetal toxicity (REMS programme in US: women must use contraception, monthly pregnancy test)
Frequently Asked Questions
Is pulmonary arterial hypertension the same as “high blood pressure”?
No. Systemic hypertension is raised pressure in the general circulation and is very common; PAH is raised pressure in the pulmonary circulation specifically and is rare. They have different causes, different specialists (PAH care is typically by pulmonology/cardiology teams at tertiary centres), and very different drug treatments. A drug that lowers systemic BP (ACEi, ARB, CCB, thiazide) usually has little effect on PAH.
Why does Rioci 1 require specialist monitoring?
PAH is a specialist-managed disease with a registry-based surveillance model in most countries. The drugs are expensive, have specific adverse effects (particularly hepatotoxicity for ERAs and hypotension for sGC stimulators), and dose-titration depends on serial assessments (6-minute walk, functional class, NT-proBNP, echocardiography). Off-label self-management carries high risks of clinical deterioration.
Can I take Rioci 1 with erectile dysfunction drugs?
No — absolutely contraindicated. PDE5 inhibitors (sildenafil, tadalafil, vardenafil) combined with riociguat cause severe additive hypotension. If you need ED therapy, discuss alternatives with your PAH team; some PAH regimens use PDE5 inhibitors instead of riociguat as the pulmonary vasodilator.
Can I take Rioci 1 in pregnancy?
No. Embryofetal toxicity documented in animal studies; pregnancy testing and contraception required.
Where can I buy Rioci 1 online?
You can buy Rioci 1 (riociguat 1 mg, 10-180 tablets) from MedsBase with discreet packaging and worldwide shipping.
Related Cardiovascular Medications
- Cardace — Ramipril (ACE inhibitor)
- Ecopril — Clopidogrel 75 mg (antiplatelet)
- Ecosprin — Aspirin 75/150 mg (antiplatelet)
- Lonitab — Minoxidil 5 mg (oral vasodilator)
- Waf-5 — Warfarin 5 mg (VKA)
- Xarelto 20 — Rivaroxaban 20 mg (DOAC)
- Browse all High Blood Pressure Medications
Related Alternatives
Other products in Chronic Conditions that customers also view:
More options in High Blood Pressure Medication
Ranked by recent MedsBase order volume — what other customers in this category are picking.
| Strength | 1 mg |
|---|---|
| Quantity | 10 Tablet/s, 30 Tablet/s, 60 Tablet/s, 90 Tablet/s, 180 Tablet/s |
Rioci 1
Ερωτήσεις & Απαντήσεις
Rioci 1
Σχετικά προϊόντα
Κριτικές
Δεν υπάρχουν ακόμη κριτικές